Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer. 1994;69:957–960. [PMC free article][PubMed]
Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol. 2003;14:291–297. [PubMed]
Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56:2097–2102. [PubMed]
Andrews PL, Bhandari P. Resiniferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology. 1993;32:799–806. [PubMed]
Andrews PL, Horn CC. Signals for nausea and emesis: implications for models diseases. Auton Neurosci. 2006;125:100–115. [PMC free article][PubMed]
Andrews PL, Torii Y, Saito H, Matsuki N. The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol. 1996;307:305–313. [PubMed]
Andrews PL, Okada F, Woods AJ, Hagiwara H, Kakaimoto S, Toyoda M, et al. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol. 2000;130:1247–1254. [PMC free article][PubMed]
Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 2003;1:46. [PMC free article][PubMed]
Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002;137:589–596. [PMC free article][PubMed]
Bartlett N, Koczwara B. Control of nausea and vomiting after chemotherapy: what is the evidence? Int Med J. 2002;32:401–407. [PubMed]
Berger B. Conditioning of food aversions by injections of psychoactive drugs. J Comp Phys Psychol. 1972;81:21–26. [PubMed]
Billig I, Yates BJ, Rinaman L. Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1243–R1255.[PubMed]
Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987;1:470–480.[PubMed]
Borrison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5:193–230.[PubMed]
Breslin PA, Spector AC, Grill HJ. A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci. 1992;106:820–836. [PubMed]
Carey MP, Burish TG, Brenner DE. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med. 1983;99:106–114. [PubMed]
Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physciol Regul Integr Comp Physiol. 2007;293:R2185–R2193. [PubMed]
Cluny NL, Naylor RJ, Whittle BA, Javid FA. The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol. 2008;103:150–156.[PubMed]
Cluny NL, Chambers AP, Limebeer CL, Keenan CM, Bedard H, Vemuri VK, et al. A novel, peripherally resitricted cannabinoid 1 (CB1) receptor antagonist AM6545 recuces food intake and body weight, but does not cause malaise in rodents. Br J Pharmacol. 2010;161:629–642. [PMC free article][PubMed]
Coil JD, Hankins WG, Jenden DJ, Garcia J. The attenuation of a specific cue-to-consequence association by antiemetic agents. Psychopharmacology. 1978;56:21–25. [PubMed]
Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: a double blind study. Med Oncol Tumor Pharmacother. 1986;3:39–42. [PubMed]
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, DiMarzo V. immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139:1405–1415. [PubMed]
Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology. 2007;190:135–143. [PubMed]
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988;24:685–689. [PubMed]
Darmani NA. Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology. 2001a;24:198–203. [PubMed]
Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav. 2001b;69:239–249. [PubMed]
Darmani NA. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001c;430:49–58. [PubMed]
Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta (9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther. 2002;300:34–42. [PubMed]
Darmani NA, Johnson CJ. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol. 2004;488:201–212. [PubMed]
Darmani NA, Janoyan JJ, Kumar N, Crim JL. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav. 2003;75:777–787. [PubMed]
Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, DiMarzo V. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology. 2005;49:502–513. [PubMed]
Davey VA, Biederman GB. Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J Exp Psychol Anim Behav Process. 1998;24:483–491. [PubMed]
deBoer-Dennert M, deWit R, Schmitz I, Djontono J, Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemothareapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–1061.[PMC free article][PubMed]
Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’ Prostaglandins Leukot Essent Fatty Acids. 1995;53:1–11. [PubMed]
Di Marzo V, Lastres-Becker I, Bisogno T, DePetrocellis L, Milone A, Davis JB, et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun. 2001;262:275–284. [PubMed]
Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73:907–910. [PubMed]
Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl ceramic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005;313:352–358.[PubMed]
Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol. 1989;4:159–165. [PubMed]
Ferrari F, Ottanik A, Giuliani D. Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug. Pharmacol Biochem Behav. 1999;62:75–80. [PubMed]
Gadusek FJ, Kalat JW. Effects of scopolamine on retention of taste-aversion learning in rats. Physiol Psychol. 1975;3:130–132.
Gamzu E. The multifaceted nature of taste aversion inducing agents: is there a single common factor? In: Barker L, Domjan M, Best M, editors. Learning Mechanisms of Food Selection. Waco, TX: Baylor Univ. Press; 1977. pp. 447–511.
Garcia J, Hankins WG, Rusiniak KW. Behavioral regulation of the milieu interne in man and rat. Science. 1974;185:824–831. [PubMed]
Garcia J, Rusiniak KW, Brett LP. Conditioning food-illness aversions in wild animals: caveant canonici. In: Davis H, Hurowitz HMB, editors. Operant Pavlovian Interactions. Hillsdale: NJ: Lawrence Erlbaum; 1977. pp. 273–316.
Gorzalka B, Hanson L, Harrington J, Killam S, Campbell-Meiklejohn D. Conditioned taste aversion: modulation by 5-HT receptor activity and corticosterone. Eur J Pharamcol. 2003;47:129–134.[PubMed]
Grelot L, Milano S, LeStunff H. Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In: Reynolds J, Andrews PLR, Davis CJ, editors. Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford: Oxford Clinical Communications; 1995. pp. 181–191.
Grigson PS, Twining R. Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards. Behav Neurosci. 2002;116:321–333. [PubMed]
Grill HC, Norgren R. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res. 1978;143:263–279. [PubMed]
Grinspoon L, Bakalar JB. Marijuana: The Forbidden Medicine. New Haven: Yale University Press; 1993.
Gupta YK, Sharma SS. Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs. Indian J Physiol Pharmacol. 2002;46:463–467. [PubMed]
Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 2005;6:35–42. [PubMed]
Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience. 2002;109:541–460. [PubMed]
Hermann H, DePetrocellis L, Bisogno T, Schiano-Morello A, Lutz B, DiMarzo V. Dual effect of cannabinoid CB1 recptor stimulation on a vanniloid VR receptor-mediated response. Cell Mol Life Sci. 2003;60:607–616. [PubMed]
Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074–1080. [PubMed]
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer. 2003;97:2880–2886. [PubMed]
Hillsley K, Grundy D. Serotonin and cholecystokinin activate different populations of rat mesenteric vagal afferents. Neurosci Lett. 1998;255:63–66. [PubMed]
Himmi T, Dallaporta M, Perrin J, Orsini JC. Neuronal responses to delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol. 1996;312:273–279. [PubMed]
Himmi T, Perrin J, El Ouazzani T, Orsini JC. Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol. 1998;359:49–54. [PubMed]
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;1111:106S–1112. [PubMed]
Howlett AC, Barth F, Bonner TI, Cabral P, Casellaa G, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev. 2002;54:161–202.[PubMed]
Iversen LL. The Science of Marijuana. New York: Oxford University Press; 2000.
Javid FA, Naylor RJ. The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus. Pharmacol Biochem Behav. 2006;5:820–826. [PubMed]
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167–179. [PubMed]
Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41:199–205. [PubMed]
Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor. Biol Pharm Bull. 1998;21:224–226. [PubMed]
Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew) Psychopharmacology. 2004;174:254–259. [PubMed]
Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, et al. Prevention of nausea and vomiting following breast surgery. Am J Surg. 2006;191:767–772. [PubMed]
Limebeer CL, Parker LA. Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport. 1999;26:371–384. [PubMed]
Limebeer CL, Parker LA. Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process. 2000;26:371–384.[PubMed]
Limebeer CL, Parker LA. The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology. 2003;166:120–126. [PubMed]
Limebeer CL, Parker LA, Fletcher P. 5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping, but not conditioned taste avoidance, in rats. Behav Neurosci. 2004;118:1391–1399. [PubMed]
Limebeer CL, Hall G, Parker LA. Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav. 2006;88:398–403. [PubMed]
Limebeer CL, Krohn JP, Rock EM, Cross-Mellor SK, Parker LA, Ossenkopp KP. Exposure to a context previously associated with toxin(LiCl)- or motion-induced sickness elicits conditioned gaping in rats: evidence in support of a model of anticipatory nausea. Behav Brain Res. 2008;187:33–40. [PubMed]
Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, et al. Inverse agonism of CB1 recpotrs potentiates LiCl-induced nausea: evidence from the conditioned gaping model in rats. Br J Pharmacol. 2010;161:336–349. [PMC free article][PubMed]
Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioural effects. Nat Chem Biol. 2009a;5:37–44. [PMC free article][PubMed]
Long JZ, Nomura DK, Cravatt BF. Characterization of Monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol. 2009b;16:744–753.[PMC free article][PubMed]
Lucot JB. Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol Biochem Behav. 1990;37:283–287. [PubMed]
Lucot JB, Crampton GH. 8-OH DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav. 1989;33:627–631. [PubMed]
McCarthy LE, Borison HL. Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol. 1981;21:30S–37S. [PubMed]
McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD. The cannabinoid antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology. 2005;180:286–293. [PubMed]
Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H. Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: a new experimental model. Jpn J Pharmacol. 1988;48:303–306.[PubMed]
Meachum CL, Bernstein IL. Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav. 1992;52:895–899. [PubMed]
Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol. 2005;146:913–915. [PMC free article][PubMed]
Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42:11S–19S. [PubMed]
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533–543. [PubMed]
Miner WJ, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986;88:497–499. [PMC free article][PubMed]
Morrow GR, Dobkin PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioral interventions. Clin Psychol Rev. 1988;8:517–556.
Nesse RM, Carli T, Curtis GC, Kleinman PD. Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med. 1980;42:33–36. [PubMed]
Okada F, Torii Y, Saito H, Matsuki N. Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus. Jpn J Pharmacol. 1994;64:109–114. [PubMed]
Parker LA. Nonconsummatory and consummatory behavioral CRs elicited by lithium-paired and amphetamine-paired flavors. Learn Motiv. 1982;13:281–303.
Parker LA. Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Rev. 1995;19:143–151. [PubMed]
Parker LA. Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol. 1998;12:3–13.
Parker LA. Taste avoidance and taste aversion: evidence for two different processes. Learn Behav. 2003;31:165–172. [PubMed]
Parker LA, Kemp S. Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV) Neuroreport. 2001;12:749–751.[PubMed]
Parker LA, Limebeer CL. Cannabinoids in the management of nausea and vomiting. In: Kofalvi A, editor. Cannabinoids and the Brain. New York: Springer-Verlag Press; 2008.
Parker LA, McLeod KB. Chin rub CRs may reflect conditioned sickness elicited by a lithium-paired sucrose solution. Pharmacol Biochem Behav. 1991;40:983–986. [PubMed]
Parker LA, Mechoulam R. Cannabinoid agonists and an antagonist modulate conditioned gaping in rats. Integr Physiol Behav Sci. 2003;38:134–146.
Parker LA, Corrick ML, Limebeer CL, Kwiatkowska M. Amphetamine and morphine produce a conditioned taste and place preference in the house musk shrew (Suncus murinus) J Exp Psychol Anim Behav Process. 2002a;28:75–82. [PubMed]
Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolg suppress nausea in an experimental model with rats. Neuroreport. 2002b;13:567–570. [PubMed]
Parker LA, Mechoulam R, Shlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology. 2003;166:156–162. [PubMed]
Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacology. 2004;171:156–161. [PubMed]
Parker LA, Limebeer CL, Kwiatkowska M. Cannabinoids: effects on vomiting and nausea in animal model. In: Mechoulam R, editor. Cannabinoids As Therapeutics. Switzerland: Birkhauser Verlag, Basel; 2005. pp. 183–200.
Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav. 2006;87:61–71.[PubMed]
Parker LA, Rana SA, Limebeer CL. Conditioned disgust, but not conditioned taste avoidance: a measure of conditioned nausea in rats. Can J Exp Psychol. 2008;6:198–209. [PubMed]
Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, and Piomelli D. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew) Physiol Behav. 2009a;97:121–124. [PMC free article][PubMed]
Parker LA, Limebeer CL, Rana SA. Conditioned disgust, but not conditioned taste avoidance, may reflect conditioned nausea in rats. In: Reilly S, Schachtman TR, editors. Conditioned Taste Aversions: Behavioral and Neural Processes. NY: Oxford University Press; 2009b.
Pertwee RG. In: The Pharmacology and Therapeutic Potential of Cannabidiol. DiMarzo V, editor. Cannabinoids: Kluver Academic/Plenum Publishers; 2004.
Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009;156:397–411. [PMC free article][PubMed]
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA. 2006;295:761–775. [PubMed]
Rabin BM, Hunt WA. Effects of anti-emetics on the acquisition and recall of radiation and lithium chloride induced conditioned taste aversions. Pharmacol Biochem Behav. 1983;18:629–636. [PubMed]
Racz I, Bilkei-Gorzo A, Markert A, Stamer F, Göthert M, Zimmer Z. Anandamide effects on 5-HT3receptors in vivo. Eur J Pharmacol. 2008;596:98–101. [PubMed]
Ray AP, Griggs L, Darmani NA. Δ9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res. 2009;196:30–36. [PMC free article][PubMed]
Reicher MA, Holman EW. Location preference and flavor aversion reinforced by amphetamine in rats. Anim Learn Behav. 1977;5:343–346.
Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the antiemetic 5HT-3 receptor antagonist granisetron. Brain Res. 1991;565:321–336. [PubMed]
Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol. 2008;196:389–395. [PubMed]
Rock EM, Limebeer CL, Fletcher PJ, Mechoulam R, Parker LA. Cannabidiol (the non-psychoactive component of cannabis) may act as a 5-HT1A auto-receptor agonist to reduce toxin-induced nausea and vomiting. CA: Poster presented at the Society for Neuroscience meeting, San Diego; 2010.
Rudd JA, Naylor RJ. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol. 1996;118:209–214. [PMC free article][PubMed]
Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol. 1996;119:931–936. [PMC free article][PubMed]
Rudd JA, Ngan MP, Wai MK. 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol. 1998;352:143–149. [PubMed]
Russo EB, Burnett A, Hall B, Parker KK. Agonist properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037–1043. [PubMed]
Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:571–572. [PubMed]
Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, et al. Arvanil, anandamide and N-arachidonolyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci. 2007;25:2773–2782. [PubMed]
Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, et al. The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology. 2001;94:882–886.[PubMed]
Sink KS, McLaughlin PJ, Brown C, Xu W, Fan P, Vemuri VK, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2007;33:1–10. [PMC free article][PubMed]
Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5S:1–9. [PubMed]
Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BJ, et al. Effect of MAGL inhibitor, JZL184, on LiCl-induced emesis in the Suncus murinus and 2-AG on LiCl-induced conditioned gaping (a model of nausea) in rats. CA: Poster presented at the Society for Neuroscience, San Diego; 2010.
Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ. Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci. 1993;28:177–181. [PubMed]
Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953–2966. [PMC free article][PubMed]
Torii Y, Saito H, Matsuki N. Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol. 1991;55:107–113. [PubMed]
Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:1–8.[PMC free article][PubMed]
Travers JB, Norgren R. Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci. 1986;100:544–555. [PubMed]
Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomized comparison of ondansetron plus dexamethasone with desamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37:2398–2404. [PubMed]
Tuerke KJ, Limebeer CL, Lester J, Chambers J, Fletcher PJ, Parker LA. Depletion of serotonin in the insular cortex by 5,7-Dihydroxytrptamine (5,7-DHT) lesions attenuates conditioned nauea in rats. 2010. Poster presented at the Society for Neuroscience meetings, San Diego.
Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci. 1987;43:513–518. [PubMed]
Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG. Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology. 1984;150:598–599. [PubMed]
Van Belle S, Lichinitser M, Navari R, Garin AM, Decramer ML, Riviere A, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK869. Cancer. 2002;94:3032–3041. [PubMed]
Van der Stelt M, DiMarzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem. 2004;271:1827–1834. [PubMed]
Van Sickle MD, Oland LD, HO W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–774. [PubMed]
Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Δ9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol. 2003;285:G566–G576. [PubMed]
Van Sickle MD, Cuncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–332.[PubMed]
Wang Y, Ray AP, McClanahan BA, Darmani NA. The antiemetic interaction of Δ9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav. 2009;91:367–373. [PMC free article][PubMed]
Wegener G, Smith DF, Rosenberg R. 5-HT1A receptors in lithium-induced conditioned taste aversion. Psychopharmacol. 1997;133:51–54. [PubMed]
Wise R, Yokel P, DeWit H. Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science. 1976;191:1273–1274. [PubMed]
Wolff MC, Leander JD. Antiemetic effects of 5-HT1A agonists in the pigeon. Pharmacol Biochem Behav. 1994;49:385–391. [PubMed]
Wolff MC, Leander JD. Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3antagonists in the pigeon. Pharmacol Biochem Behav. 1995;52:571–575. [PubMed]
Wolff MC, Leander JD. Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol. 1997;340:217–220. [PubMed]
Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, et al. Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol. 2002;442:273–278.[PubMed]
Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M. The nonpsychoactive cannabinoid cannabidiol inhibits 5-Hydroxytryptamine3A receptor-mediated currents in Xenopus laevis Oocytes. J Pharmacol Exp Therap. 2010;333:547–554. [PMC free article][PubMed]